CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

Mark Wong, Rosemary L. Balleine, Michael Collins, Christopher Liddle, Christine L. Clarke, Howard Gurney

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population.

Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients.

Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA).

Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.

LanguageEnglish
Pages529-538
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume75
Issue number6
DOIs
Publication statusPublished - Jun 2004
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP3A
Midazolam
Genotype
Drug Therapy
Single Nucleotide Polymorphism
Neoplasms
Heterozygote

Cite this

Wong, Mark ; Balleine, Rosemary L. ; Collins, Michael ; Liddle, Christopher ; Clarke, Christine L. ; Gurney, Howard. / CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. In: Clinical Pharmacology and Therapeutics. 2004 ; Vol. 75, No. 6. pp. 529-538.
@article{73b746c2d4054c48bab6d6695d17dc6a,
title = "CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy",
abstract = "Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population. Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients. Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13{\%}) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10{\%}) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95{\%} confidence interval, 1.15-2.51; P = .01, 2-way ANOVA). Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.",
author = "Mark Wong and Balleine, {Rosemary L.} and Michael Collins and Christopher Liddle and Clarke, {Christine L.} and Howard Gurney",
year = "2004",
month = "6",
doi = "10.1016/j.clpt.2004.02.005",
language = "English",
volume = "75",
pages = "529--538",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Springer, Springer Nature",
number = "6",

}

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. / Wong, Mark; Balleine, Rosemary L.; Collins, Michael; Liddle, Christopher; Clarke, Christine L.; Gurney, Howard.

In: Clinical Pharmacology and Therapeutics, Vol. 75, No. 6, 06.2004, p. 529-538.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

AU - Wong, Mark

AU - Balleine, Rosemary L.

AU - Collins, Michael

AU - Liddle, Christopher

AU - Clarke, Christine L.

AU - Gurney, Howard

PY - 2004/6

Y1 - 2004/6

N2 - Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population. Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients. Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA). Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.

AB - Objectives: Cytochrome P450 (CYP) 3A enzymes are key metabolizing enzymes for many chemotherapeutic agents, and detection of functionally significant CYP3A genetic variants may be useful in predicting interpatient variation of drug clearance. We have examined the significance of CYP3A5*3 single-nucleotide polymorphism to overall CYP3A activity in vivo in a predominantly Caucasian Australian cancer population. Methods: Screening for wild-type CYP3A5*1 and CYP3A5*3 single nucleotide polymorphism by use of Taqman MGB probe allelic discrimination was performed in 67 patients with cancer (58 Caucasian patients). CYP3A activity was documented via clearance of either oral or intravenous midazolam in 64 patients. Results: All patients had at least 1 CYP3A5*3 allele, and 9 (13%) patients were heterozygous for CYP3A5*3 and CYP3A5*1. Within the subset of Caucasian patients, 6 of 58 (10%) were CYP3A5*1/*3 heterozygotes. Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P = .01, 2-way ANOVA). Conclusion: Overall CYP3A activity is related to CYP3A5 genotype. CYP3A5 genotyping may be helpful in predicting the drug-metabolizing capability of individual cancer patients who are predominantly Caucasian in origin.

UR - http://www.scopus.com/inward/record.url?scp=2942560581&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2004.02.005

DO - 10.1016/j.clpt.2004.02.005

M3 - Article

VL - 75

SP - 529

EP - 538

JO - Clinical Pharmacology and Therapeutics

T2 - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -